Form 4 for NVCR NovoCure Ltd
Accepted 2023-01-09 00:00:00 ET · period of report 2023-01-05 · accession 0001645113-23-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-09 | 2023-01-05 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $108.00 | -387 | 82.8K | -0.5% | -$41.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-01-05 | S | D | 387 | $108.00 | 82,843 | D | — | — | (F1) Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. |